TY - JOUR KW - Confidence Intervals KW - Disability Evaluation KW - Drug Therapy, Combination KW - Ethiopia KW - Humans KW - Incidence KW - Leprostatic Agents KW - leprosy KW - Neuritis KW - Neurologic Examination KW - Preventive Health Services KW - Skin Tests KW - World Health Organization AU - Rijk A J AU - Gabre S AU - Byass P AU - Berhanu T AB -

For a cohort of 286 leprosy patients the incidence rates and clinical manifestations of leprosy reactions during treatment and surveillance are described. Currently, individual patients had been observed for up to 4 years. It is intended that surveillance within this project should continue for up to 5 years after treatment. Of 128 PB patients, observed for 267 person-years (mean 2.1) 27 had 35 episodes of reaction, corresponding to an overall incidence rate of 131 events per 1000 person-years-at-risk (pyar). Of 158 MB patients observed for 402 person years (mean 2.5), 64 had 114 reactions, with an overall incidence of 284 events per 1000 pyar. For both PB and MB patients, incidence rates during treatment and post-MDT surveillance were similar. For PB patients, pre-existing physical impairment at the start of MDT was a significant risk factor for the occurrence of subsequent events, but this was not found in MB patients.

BT - Leprosy review C1 - http://www.ncbi.nlm.nih.gov/pubmed/7861918?dopt=Abstract CN - DERIJK1994 DA - 1994 Dec DO - 10.5935/0305-7518.19940033 IS - 4 J2 - Lepr Rev LA - eng N2 -

For a cohort of 286 leprosy patients the incidence rates and clinical manifestations of leprosy reactions during treatment and surveillance are described. Currently, individual patients had been observed for up to 4 years. It is intended that surveillance within this project should continue for up to 5 years after treatment. Of 128 PB patients, observed for 267 person-years (mean 2.1) 27 had 35 episodes of reaction, corresponding to an overall incidence rate of 131 events per 1000 person-years-at-risk (pyar). Of 158 MB patients observed for 402 person years (mean 2.5), 64 had 114 reactions, with an overall incidence of 284 events per 1000 pyar. For both PB and MB patients, incidence rates during treatment and post-MDT surveillance were similar. For PB patients, pre-existing physical impairment at the start of MDT was a significant risk factor for the occurrence of subsequent events, but this was not found in MB patients.

PY - 1994 SP - 320 EP - 32 T2 - Leprosy review TI - Field evaluation of WHO-MDT of fixed duration, at ALERT, Ethiopia: the AMFES project--II. Reaction and neuritis during and after MDT in PB and MB leprosy patients. UR - http://leprev.ilsl.br/pdfs/1994/v65n4/pdf/v65n4a05.pdf VL - 65 SN - 0305-7518 ER -